Vyome develops treatments for rare and immune inflammatory diseases and sells antifungal products in India. It last closed at $1.51 on Nov 17, up 0.67% on the day.
Only 1 firm rated HIND in the past 90 days, not enough for a consensus
Average 12-month target
$3.50
▲ 131.8% upside
Based on 1 analyst who set a price target on HIND in the past 90 days. The average target is $3.50, with a high of $3.50 and a low of $3.50, compared with the last close of $1.51.
Low $3.50Avg $3.50High $3.50
Blue marker: last close $1.51
Highest target$3.50
Average target$3.50
Lowest target$3.50
Latest rating changes
Chardan CapitalInitiated
Sep 3Buy$3.50
Date
Firm
Action
Rating
Price target
Sep 3
Chardan Capital
Initiated
Buy
$3.50
Loading…
Technical Analysis
HIND · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 11% below its 20 day and 23% below its 50 day average. It is 44% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $1.49, and the nearest resistance the Pivot at $1.52.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 6.5%/day
Key levels
$5.8852 week high+289.4%
$2.18200 day average+44.4%
$2.02100 day average+33.8%
$1.8650 day average+23.2%
$1.72Swing high (Nov 11)+13.9%
$1.6820 day average+11.3%
$1.54Pivot R1+2.0%
$1.52Pivot+0.7%
$1.51Last close
$1.4952 week low−1.3%
$1.48Pivot S1−2.0%
Indicators
RSI (14)
29.75
Oversold below 30
Oversold
MACD
-0.10
Below its signal line
Bearish
Stochastic
4.3
Near the bottom of its range
Oversold
ADX (14)
13.7
No clear trend
Williams %R
-96.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-117.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−14.7%
Change over 10 sessions
Bearish
ATR (14)
$0.10
Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityLow, 36.9%/day
Key levels
$5.8852 week high+289.4%
$2.18200 day average+44.4%
$2.02100 day average+33.8%
$1.8650 day average+23.2%
$1.72Swing high (Nov 11)+13.9%
$1.6820 day average+11.3%
$1.54Pivot R1+2.0%
$1.52Pivot+0.7%
$1.51Last close
$1.4952 week low−1.3%
$1.48Pivot S1−2.0%
Indicators
RSI (14)
26.16
Oversold below 30
Oversold
MACD
-0.85
Above its signal line
Bullish
Stochastic
3.6
Near the bottom of its range
Oversold
ADX (14)
3.0
No clear trend
Williams %R
-97.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-190.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−26.7%
Change over 10 sessions
Bearish
ATR (14)
$0.56
Typical daily range, 36.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for HIND
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how HIND did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in HIND in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HIND is in one of them and how their past HIND trades turned out.
Vyome is a clinical stage specialty pharmaceutical company developing treatments for immune inflammatory and rare diseases. Its lead program is a topical gel for symptoms of malignant fungating wounds in advanced cancer. Its other development programs target uveitis, an eye condition, and moderate to severe acne, and none of its candidates is approved for sale. The company also sells dandruff lotion and shampoo, both antifungal products, in India through a licensing partner, Sun Pharma. It is based in San Clemente, California, with operations in Massachusetts, New Jersey and New Delhi, India.